Development of a Specific Cell-based Platform to Analyze Proteolytic Activity of Cancer Relevant Serine Proteases by Peltonen, Satu
  
 
 
 
 
 
 
 
 
 
 
 
 
Satu Peltonen 
 
Development of a Specific Cell-based  
Platform to Analyze Proteolytic Activity  
of Cancer Relevant Serine Proteases 
Helsinki Metropolia University of Applied Sciences 
Bachelor of Engineering 
Biotechnology and Food Engineering 
Final Thesis 
30.05.2015 
 Abstract 
  
Author(s) 
Title 
 
Number of Pages 
Date 
Satu Peltonen 
Development of a Specific Cell-based Platform to Analyze 
Proteolytic Activity of Cancer Relevant Serine Proteases 
70 pages + 6 appendices  
30 May 2015 
Degree Bachelor of Engineering 
Degree Programme Biotechnology and Food Engineering 
Specialization option Biomedicine 
Instructor(s) 
 
Topi Tervonen, PhD 
Tiina Soininen, Phil. Lic., Lecturer 
Serine proteases modify the cell's internal and external environment, whereas their most 
important role is in activating or inactivating other proteins by cleavage and their 
dysregulation is one feature of cancer. They are particularly implicated in tumor growth, 
invasion and metastasis. Serine proteases are associated with diverse cancer types and 
pathologies, such as ovarian and prostatic cancer, but also inflammatory and viral diseas-
es. Serine proteases are widely studied as biomarkers and drug targets in drug discovery 
although compounds with good pharmacokinetic properties have been difficult to obtain. 
The aim of this thesis was to develop an enzymatic assay targeting hepsin, which is asso-
ciated inter alia with breast cancer. The development project was made for the Cancer Cell 
Circuitry Laboratory that is investigating oncogenes and tumor suppressors in breast can-
cer. The Cancer Cell Circuitry Laboratory is part of the Translational Cancer Research 
Program in Institute of Biomedicine in University of Helsinki. The development project con-
sisted of two assay formats, namely biochemical assay and cell-based assay. The bio-
chemical assay was optimazed and further developed from a commercial protocol based 
on recombinant hepsin by R&DSystems. The development of cell-based assay was based 
on doxycycline inducible hepsin expressed in non-malignant mammary epithelial MCF 10A 
cells. 
Final assay design parameters includes 0.1 nM rhHepsin, 15 µM BOC, 6 µM positive con-
trol and 0.3 % DMSO. The functionality of the biochemical assay was verified by signal 
variability assessment and further ascertained by the compound screening. It should be 
noted that the compounds are exposed to changes in room temperature during incubation 
which leads to significant variations in results regarding compounds. 
The development of the cell-based assay could not be finalized due to the extent of the 
project and lack of time caused by replacement of the original equipment. Since the time 
scope was too limited for a thorough experimental design, all results can be considered 
indicative. The vital point is to ensure cell viability after seeding to 96-well plate as it is the 
main source of variation. Another aspect is the usage of doxycyclin which may lead to a 
combined reaction with the substrate.  
Keywords cancer, serine proteinase inhibitors, proteolysis, screening 
analysis, drug design 
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Seriiniproteaasit muokkaavat solun ulkoista ja sisäistä ympäristöä, missä niiden tärkein 
rooli on muiden proteiinien pilkkominen aktiivisiksi tai inaktiivisiksi, ja niiden säätelyhäiriö 
on yksi syövän tunnusmerkeistä. Erityisesti ne osallistuvat tuumorin kasvuun, invaasioon ja 
etäpesäkkeiden leviämiseen. Seriiniproteaasit on liitetty erilaisiin syövän lajeihin ja saira-
uksiin, kuten munasarjojen ja eturauhasen syöpiin, mutta myös tulehdus- ja virustauteihin. 
Seriiniproteaaseja on laajalti tutkittu lääkekehityksen kohteina, vaikka hyvien farmakoki-
neettisten ominaisuuksien omaavia yhdisteitä on ollut vaikea löytää. 
 
Opinnäytetyön tavoitteena oli kehittää entsymaattinen määritysalusta, jonka kohteena on  
hepsin, joka liittyy muun muassa rintasyöpään. Kehittämishanke tehtiin Cancer Cell Cir-
cuitry laboratoriolle, joka tutkii rintasyöpään liittyviä onkogeenejä ja tuumorisuppressoreita. 
Cancer Cell Circuitry laboratorio on osa Biomedicumin Biolääketieteen laitoksen Transla-
tionaaalisen syöpätutkimuksen ohjelmaa. Kehittämishanke koostui kahdesta formaatista eli 
biokemiallisesta määritysalustasta ja solupohjaisesta määritysalustasta. Biokemiallinen 
määritysalusta optimointiin ja edelleen kehitettiin kaupallisesta protokollasta, joka perustui  
R&DSystemsin rekombinanttiin hepsiniin. Solupohjaisen määritysalustan kehittämisen 
perustana käytettiin hyvänlaatuista MCF 10A rintaepiteelisolulinjaa, jossa hepsiinin eks-
pressio indusoitiin doksysykliinillä. 
 
Valmis biokemiallinen määritysalusta pitää sisällään 0.1 nM rhHepsiiniä, 15 µM BOC sub-
straattia, 6 µM positiivista kontrollia ja 0.3 % DMSO:ta. Biokemiallisen määritysalustan 
toimivuus varmistettiin signaalin vaihtelun arvioinnilla sekä edelleen todentamalla yhdistei-
den seulonnan yhteydessä. Huomattavaa on, että yhdisteet altistuvat inkubaation aikana 
huonelämpötilan vaihteluille, mikä johtaa merkittäviin vaihteluihin tuloksissa yhdisteiden 
osalta. 
 
Solupohjaista määritysalustaa ei voitu saattaa päätökseen projektin laajuudesta sekä al-
kuperäisen laitteiston korvaamisesta johtuvan ajan puutteen vuoksi. Aikarajoituksesta joh-
tuen testisuunnitelmia ei voitu perusteellisesti käydä läpi, joten tuloksia voidaan pitää alus-
tavina. Olennaisinta on varmistaa solujen elinkelpoisuus 96-kuoppalevylle kylvön jälkeen, 
sillä tämä on suurin vaihtelun aiheuttaja tuloksissa. Toinen näkökohta on doxycyclinin käyt-
tö, mikä saattaa johtaa yhteisvaikutukseen substraatin kanssa. 
Avainsanat syöpä, seriiniproteinaasin estäjät, proteolyysi, seulonta, lääke-
suunnittelu 
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1 Introduction 
 
This thesis was made for the Cancer Cell Circuitry Laboratory that is part of the Trans-
lational Cancer Research Program in Institute of Biomedicine, Biomedicum Helsinki. 
The Cancer Cell Circuitry Laboratory is studying oncogenes and tumor suppressors in 
breast cancer. 
 
Proteases are important signaling molecules in pericellular environment and they have 
been under study for their role in pathologies including cancer. Serine proteases par-
ticularly are regularly connected to tumor progression and metastases in diverse can-
cer types, and their dysregulation is one feature of cancer although their mechanism of 
action has not been fully elucidated. One of the most studied subtypes are membrane-
anchored serine proteases as they have been associated with such cancer types as 
pancreatic, gastric, colorectal, lung, ovarian and thyroid cancer but also with such 
pathological diseases as cardiovascular, inflammatory and viral diseases. 
 
Serine proteases have been studied extensively as biomarkers in drug discovery. Alt-
hough there are several serine protease inhibitors in clinical use, obtaining compounds 
with good pharmacokinetic properties has been challenging. The first step in develop-
ing an enzyme inhibitor is the identification of proteases and their inhibitors in diseases 
through their differential expression. In case of proteases, the expression profile re-
mains often unchanged. 
 
The aim of the project was to develop an enzymatic assay targeting hepsin, which is a 
membrane-anchored serine protease. The objective was to develop two different as-
says for screening compounds with pharmacokinetic properties. Namely, a biochemical 
assay using recombinant hepsin and a cell-based assay using MCF 10A-pINDUCER-
NEO-HPN cells. 
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2 Introduction to Proteolytic Enzymes 
 
Proteolytic enzymes, also known as proteases, are a family of enzymes that catalyze 
the cleavage of proteins by hydrolyzing peptide bonds. Proteases have an essential 
role as signaling molecules that regulate numerous biological processes such as DNA 
replication, cell-cycle progression, cell proliferation and cell death, tissue remodeling, 
wound healing, blood coagulation, and the immune response. (Turk 2006) 
 
Proteases are known to regulate diverse processes in the pericellular microenviron-
ment that are essential for cancer biology, including proliferation, adhesion, migration, 
differentiation, angiogenesis, senescence, autophagy, apoptosis and evasion of the 
immune system. Thus, it has been demonstrated that proteases contribute to all stages 
of tumour progression. However, the existence of tumor-suppressive proteolytic en-
zymes reveals the large structural and functional diversity of proteolytic systems oper-
ating in all stages of the disease. (López-Otin et al. 2007) 
 
Although the common feature of proteases is their ability to hydrolyze peptide bonds, 
they use two fundamentally different mechanisms to catalyze substrate cleavage, non-
covalent catalysis and covalent catalysis (Turk 2006). On the basis of mechanism of 
catalysis, all identified human proteases can be classified into five catalytic classes, 
aspartic and metalloproteases, serine, cysteine and threonine proteases. The first two 
classes utilize an activated water molecule as a nucleophile to attack the peptide bond 
of the substrate ( non-covalent catalysis), whereas in the latter three classes the nucle-
ophile is a part of an amino acid residue (Serine, Cysteine, or Threonine respectively) 
in the active site (covalent catalysis). (López-Otin et al. 2007; Turk 2006) 
 
Proteases of the different classes can be further grouped into families on a basis of 
amino acid sequence comparison which leads to the human degradome (Figure 1) that 
presents the proteases produced by human cells consisting of at least 569 proteases 
and homologues in 69 different families. Hence the human degradome can be seen as 
the complete set of proteolytic genes encoded by the human genome. (López-Otin et 
al. 2007) 
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Figure 1. Proteases in the Human Degradome. Grey line presents an individual enzyme, 
whereas the red line presents an enzyme with tumor-protective properties. (López-Otin C. & 
Matrisian L.M. 2007) 
 
Each catalytic class consists of both extracellular or pericellular enzymes as well as 
intracellular or integral-membrane enzymes. Cysteine proteases, for example, consists 
of five extracellular or pericellular enzymes and 145 intracellular or integral-membrane 
enzymes, whereas the serine proteases consists of 138 extracellular or pericellular 
enzymes and 38 intracellular or integral-membrane enzymes. (López-Otin et al. 2007) 
 
2.1 Serine Proteases 
 
Serine proteases are defined by the serine residue within their active site which func-
tions as the primary nucleophile initiating catalysis by attacking the substrate peptide 
bond (Antalis et al. 2010). Serine proteases are one of the first and most well-studied 
enzymes due to their ease of isolation and availability in large quantities in a wide 
range of tissues and biological fluids in mammals. The role of serine proteases in di-
verse cellular activities such as digestion, blood clotting cascade, inflammation and 
wound healing and general immune response has been well characterized due to an 
excessive amount of collected information. Therefore, serine proteases provide an il-
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lustrative model for substrate binding specificity and transition state stabilization of pro-
teases. (Copeland 2000) 
 
Serine proteases also have a common structural feature referred to as “active site tri-
ad” or “charge relay system” which means that in order to complete the proteolysis, the 
nucleophilicity of the serine residue is enhanced by a catalytic triad of histidine, aspar-
tate and serine residues. Virtually, the hydroxyl group of the serine side chain will form 
a hydrogen-bond with an active site histidine residue side chain, which in turn will form 
a hydrogen-bond to an active site aspartate side chain. The catalytic triad of histidine, 
aspartate and serine is included in a tertiary domain structure which has a high se-
quence homology between serine proteins as the catalytic domain structure is highly 
conserved. (Copeland 2000; Antalis et al. 2010) 
 
Serine proteases have been further grouped into families based on their amino acid 
sequence and clans based on their three-dimensional structures and other functional 
attributes. Some of the most covered serine proteases, including trypsin, chymotrypsin 
and thrombin, belong to clan PA and subfamily S1A, which is a large group of enzymes 
representing over 20 % of the known proteases, which, inter alia, participate in the acti-
vation of precursors in the pericellular microenvironment. Pericellular microenvironment 
of the cell contains proteins as inactive precursors including growth factors, cytokines, 
receptors, enzymes and cell adhesion molecules that will be activated via proteolysis 
by cell-surface-localized protease receptors, however proteolysis may also be mediat-
ed by membrane-anchored protease. (Antalis et al. 2010) 
 
2.2 Membrane-Anchored Serine Proteases 
 
Membrane-anchored serine proteases are a subgroup of thrypsin-like (S1) serine pro-
teases that possess a distinguishing domain which tether them directly to the plasma 
membrane. These membrane-anchored serine proteases are synthesized with amino- 
or carboxyl-terminal that allow them to be imbedded directly into the membrane posi-
tioning them so that their catalytic serine protease domains lie extracellular. (Netzel-
Arnett et al. 2003; Antalis et al 2011) 
 
The structural feature of the amino- or carboxyl-terminal domain allows the membrane-
anchored serine proteases to be divided into two subgroups (Figure 2), type I and type 
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II. The only type I transmembrane serine protease that has been identified is Tryptase 
ɣ1, whereas a total of nineteen TTSPs have been identified. (Antalis et al. 2011) 
 
 
Figure 2. Some of the Well Characterized S1A Serine Proteases. On the left secreted Trypsin 
following the four subgroups of type II transmembrane serine proteases. (Antalis et al. 2010) 
 
These type II transmembrane serine proteases have been further divided into four sub-
groups based on their serine protease domains and the domain structure of the extra-
cellular stem region, namely HAT/DESC (human airway trypsin-like prote-
ase/differentially expressed in squamous cell carcinoma), Matriptase, TMPRSS 
(Transmembrane Protease, Serine) and Corin. Type I is tethered to the plasma mem-
brane by hydrophobic C-terminal transmembrane domain via 
glycosylphosphatidylinositol (GPI) linkage, and it will be synthesized with a classical N-
terminal signal peptide that will be cleaved during synthesis. Type II is synthesized and 
imbedded into the plasma membrane with an N-terminal signal anchor that will not be 
cleaved during synthesis. Instead, the protease will be positioned into the membrane 
with a cytoplasmic N-terminus and extracellular C-terminus. (Antalis et al. 2010) 
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2.3 Human Hepsin 
 
Human hepsin, being part of TMPRSS subfamily, is classified as an integral membrane 
protein and a TTSP of the trypsin-like (S1) family (Antalis et al. 2010). Hepsin is en-
coded by human HPN gene – has 14 exons and is located on chromosome 19 at q11-
13.2 – and is expressed in liver (Figure 3) at higher levels and at lower levels in other 
tissues, such as kidney, pancreas, stomach, thyroid, testis and prostate. Like other 
membrane anchored serine proteases, hepsin is linked directly to the plasma mem-
brane consisting of intracellular domain, transmembrane domain and extracellular stem 
region. (Somoza et al. 2003; Xuan et al. 2006) 
 
 
Figure 3. Hepsin in Human Liver. (R&D Systems 2014) 
 
Hepsin was first identified in Earl Davie’s laboratory at the University of Washington, by 
cloning cDNA from a human hepatoma HepG2 cell library based on homology and was 
named for its hepatic expression. Hepsin is synthesized as single-chain zymogen 
which is proteolytically activated and its cDNA is ~1.8 kb in length, has a molecular 
mass of 45 kDa and encodes a polypeptide of 417 amino acids. (Xuan et al. 2006; 
Antalis et al. 2011) 
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3 Biological Role of Membrane-anchored Serine Proteases 
 
Membrane-anchored serine proteases, TTSPs particularly, are expressed at the cell 
surface and are thus ideally located to regulate cell–cell and cell–matrix interactions, 
participating in a wide range of physiological events through activation, regulation and 
mediation in many multi-components signaling events. Although many of these biologi-
cal, physiological and pathological processes in vivo remain elusive, they are consid-
ered vital for the development and maintenance of homeostasis. (Antalis et al. 2011) 
 
3.1 Zymogen Cascades 
 
Membrane-anchored serine proteases are synthesized as inactive single chain 
proenzymes, also known as zymogens, and their activation is an integral part of the 
regulation of cellular signal cascades at the plasma membrane and within the extracel-
lular matrix. Such biological processes as blood coagulation, wound healing, digestion, 
immune response, fibrinolysis, complement reaction, hormone production, metamor-
phosis and fertilization are subjected to activation of zymogen cascades. A zymogen 
cascade consists of sequential irreversible proteolytic reactions, where downstream 
zymogen is activated by cleavage by another previously activated serine protease or 
by self-activation. Due to the complexity of the protease signaling cascades the majori-
ty of the specific endogenous enzymes that catalyze the activation of the zymogen 
forms of the proteases in vivo are yet to be identified. (Netzel-Arnett et al. 2003; Antalis 
et al. 2010) 
 
One of the best characterized TTSPs that participate in zymogen activation is 
enteropeptidase which activates pancreatic trypsinogen into its bioactive form trypsin 
subsequently converting other pancreatic zymogens to their active forms during diges-
tion. Plasminogen cascade is a key cascade critical for fibrinolysis, cell migration, re-
modelling of extracellular matrix and activation of matrix metalloproteinases (MMP). 
Plasminogen cascade can be initiated by several of the TTSPs, including matriptase, 
hepsin and serase-1B in vitro assays, by activating protease zymogen pro-uPA into its 
catalytically active form. (Netzel-Arnett et al. 2003; Antalis et al. 2010) 
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3.2 Activation and Regulation 
 
Activation, inhibition and substrate specificity, as well as the cellular localization is de-
termined by the extracellular domains of TTSPs, whereby frequent ectodomain shed-
ding enables the activity of TTSPs in the pericellular microenvironment. Regulation is 
mainly mediated by endogenous inhibitors such as serpins and Kunitz-type inhibitors 
by endogenous protease inhibitors in which the main role is by Kunitz-type inhibitors 
and serpins. (Bugge et al. 2003) 
 
G-protein coupled signaling receptors on the cell surface known as protease activated 
receptors (PARs) include four family members, PAR1-4 respectively. Each family mem-
ber of the PAR family is activated either directly or indirectly through proteolytic cleav-
age by different membrane-anchored serine proteases initiating various intracellular 
signal transduction pathways. (Antalis et al. 2010.) PAR2, for example, can be activated 
by matriptase inducing the release of pro-inflammatory cytokines in endothelial cells 
including IL (interleukin)-6 and IL-8 (Netzel-Arnett et al.2003; Antalis et al. 2010). 
 
The activation and availability of growth factors are processed through proteolytic 
cleavage by membrane-anchored serine proteases such as the modulation of epider-
mal growth factor receptor (EGFR) (Netzel-Arnett et al. 2003; Antalis et al. 2010). For 
example, both matriptase and hepsin has been shown to activate growth factors func-
tioning as ligands for receptors MET/HGF and RON/MST-1 associated with epithelial 
cell motility, migration and proliferation (Antalis et al. 2010). 
 
Atrial natriuretic peptide known as ANP is a cardiac hormone, essential in regulating 
blood pressure and cardiac function by regulating systemic salt and water balance 
through natriuresis, dieresis and vasodilation. ANP is synthesized as cell-associated 
precursor molecule pro-ANP. The inactive pro-ANP is released and activated by 
proteolytic cleavage which is catalyzed by TTSP corin in a sequence-specific manner 
converting pro-ANP into its bioactive form on the surface of cardiomyocytes.  (Bugge et 
al. 2009; Antalis et al. 2011) 
 
The sodium and water flux across high resistance epithelium of airway, bladder, kid-
ney, colon and skin is regulated by epithelial sodium (Na+) channel known as ENaC 
which is activated and regulated through proteolytic processing. ENaC has been found 
to be activated by membrane-anchored serine proteases when co-expressed in heter-
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ologous expression systems, although implications of non-catalytic protease mecha-
nism involving ENaC activation has also been found. Furthermore, there is evidence 
implying that membrane-anchored serine proteases may regulate ENaC both positively 
and negatively. (Antalis et al. 2011) 
 
3.3 Biological Role of Human Hepsin 
 
Hepsin has been implicated in cell growth and maintaining cell morphology, whereas it 
has been shown that hepsin is not essential for either embryonic development or vital 
adult functions (Somoza et al. 2003; Xuan et al. 2006). Hepsin in known to activate or 
cleave pro-HGF (hepatocyte growth factor), liver microsomal glutathione transferase, 
matriptase, prostasin, EGFR, laminin and blood clotting factors VII, IX, and XII in vitro. 
Nonetheless, the physiological targets of hepsin in vivo remain largely elusive. (Antalis 
et al. 2011) 
 
Hepsin is one of the TTSPs that have demonstrated autocatalytic activation in vitro 
suggesting it may function as initiator in protelolytic cascades. The physiological 
mechacnism of autoactivation is not well undersood, but it is associated with 
oligomerization. (Bugge et al. 2009.) Hepsin has been implicated in zymogen activation 
by intercepting the blood coagulation cascade and plasminogen cascade. In blood co-
agulation cascade hepsin activates protease zymogen Factor VII into its bioactive form 
Factor VIIa, initiating a coagulation pathway on the cell surface leading to thrombin 
formation. On the other hand, in vitro assays have demonstrated that hepsin catalyses 
the activation of pro-uPA (urokinase plasminogen activator) to its active form in plas-
minogen cascade. (Antalis et al. 2010) 
4 Membrane-anchored Serine Proteases in Pathologies 
 
Mutations in several genes, encoding TTSPs has been found to entail in missing or 
truncated serine protease domains (SPDs) in TTSPs and alter enzyme expression and 
activity. For instance, chromosomal rearrangements together with altered expression of 
TTSP genes contributes to human carcinogenesis, whereas missense mutations in 
SPD of matriptase entail in catalytically inactive protease resulting to human skin dys-
function. In addition, autosomal recessive genetic disorders in humans have been re-
traced to mutations in five TTSP genes. (Antalis et al. 2010; Bugge et al. 2009) 
10 
 
  
Membrane-anchored serine proteases promote viral pathogenicity by activating and 
replicating viruses. In the pivotal role is haemagglutinin (HA), viral antigenic glycopro-
tein responsible for binding the virus to the cell that is being infected. Haemagglutinins 
proteolytic cleavage sites mutational evolution is determinant of viral pathogenicity, as 
HA is synthesized as precursor protein HA0 that must be cleaved into subunits HA1 and 
HA2 by the host cellular protease. (Antalis et al. 2010) 
 
4.1 Membrane-anchored Serine Proteases in Cancer 
 
The cellular expression of many membrane-anchored serine proteases appears to be 
aberrant during tumor development and progression in human cancer, possessing 
complex role in relation to cancer, as expression of these enzymes have been associ-
ated both up- and downregulation (Netzel-Arnett et al. 2003; Antalis et al. 2010). Nota-
bly, many of the TTSPs have been causally linked to various cancers. TMPRSS4, for 
instance, has been associated with pancreatic, gastric, colorectal, lung, and thyroid 
cancers. Matriptase, on the other hand, exemplifies consistent expression in tumors of 
epithelial origin, including prostate, ovarian, cervical, gastric, colon, renal cell, esopha-
geal, oral squamous cell carcinoma, and malignant pleural mesothelioma. In case of 
prostasin, a downregulation is documented with tumor progression. (Antalis et al. 2011) 
 
4.2 Dysregulation of Human Hepsin in Cancer 
 
Hepsin attracted interest in epithelial carsinogenesis after several analyses supported 
the role of hepsin encoding HPN gene in prostate cancer. Reportedly overexpressed 
HPN has induced metastasis in prostate epithelium in a non-metastatic murine model 
of prostate cancer, whereas catalytically active hepsin has promoted the progression of 
ovarian carcinoma cell lines. As previously mentioned, hepsin is known to cleave in 
vitro such proteins as pro-HGF, laminin 332 and pro-uPA many of which have been 
associated in carcinogenesis. (Bugge et al. 2009) 
 
In contrast to suggestion in early literature, hepsin having a role in human tumor cell 
proliferation, the recent studies support role for hepsin in tumor progression and metas-
tases (Xuan et al. 2006; Chevillet et al. 2008; Antalis et al. 2011). As demonstrated in 
studies by Klezovitch et al. 2004, whereby transgenic mice imitating hepsin overex-
pression in prostate cancer entailed to altered basement membrane structures in mice, 
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whereas prostate cell proliferation remained normal. After crossing the mice with non-
metastasizing cancer model the mice demonstrated invasive prostate cancer cells in-
ducing metastasis in the liver, lung and bone. (Xuan et al. 2006; Chevillet et al. 2008; 
Antalis et al. 2011) 
 
Furthermore, recent studies have found that hepsin mediates epithelial integrity and 
basement membrane defects as well as transformation in Lkb1-deficient (Liver kinase 
b1, STK11) 3D acini, wherein deregulated expression of hepsin is sufficient to disrupt 
epithelial integrity. In conclusion, hepsin seems to be released from junctional com-
plexes by loss of Lkb1, wherein hepsin-deregulating lesions generally promote Myc-
driven tumorigenesis as Myc does not alter the position or level of hepsin. Although the 
deregulation of hepsin by Myc coupled with Lkb1 is yet to be demonstrated in mouse 
breast cancer models, the overexpression of hepsin is implicated as a common genetic 
alteration in prostate and breast cancer. Hence, hepsin may be a potential therapeutic 
target in breast cancer. (Partanen et al. 2012) 
5 Methods in Drug Discovery 
 
High-Throughput Screening (HTS) is a method for drug discovery that is widely used in 
pharmaceutical industry. In HTS, a large number of biological modulators and selectors 
are assayed against specific targets by screening different types of biological and 
chemical libraries. (Szymański et al. 2012) Virtual screening is a computer-aided meth-
od used in drug discovery to align and score ligands based on their shape, wherein 
similar molecules are assumed to have similar binding characteristics. Prerequisite for 
virtual screening based on shape is the generation of the 3D structure of the molecule. 
(Sastry et al. 2011) On the other hand, Structure-Activity Relationship (SAR) analysis 
measures the relationship between chemical or 3D structure of the molecule with its 
biological activity, which is also used in toxicology (McKinney et al. 2000). 
 
High-Throughput Screening assays can be divided into two categories, namely bio-
chemical assays and cell-based assays. Until recently pharmaceutical industry has 
been mainly utilizing target-based biochemical assays, such as enzyme inhibition and 
receptor-ligand binding assays in High-Throughput Screening. However, cell-based 
assays have been gaining interest as they provide an early indication of the compound 
toxicity characteristics. Furthermore, cell-based assay represents tissue-specific re-
sponses of compound activity in a cellular context more accurately compared to bio-
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chemical assays that are limited by suitable compound purification and preparation 
methods. (Zang et al. 2012) 
 
5.1 Proteases as Drug Discovery Targets 
 
In order to prevent improper cleavage of signaling molecules, the protease activity is 
tightly regulated by differential expression at transcriptional level. During cell and tissue 
development and organism homeostasis, the protease activity is also regulated by zy-
mogen activation and binding of inhibitors and cofactors at protein level (Figure 4). 
(López-Otin et al. 2007) 
 
 
Figure 4. Regulation of Protease Activity. (López-Otin et al. 2007) 
 
However, once dysregulated there is an excessive or insufficient proteolysis at the 
substrate-cleavage level, mostly resulting from numerous endogenous or exogenous 
factors. This dysregulation entails to unwanted activation of protease signaling path-
ways, rather than being a consequence of genetic aberration. (López-Otin et al. 2007) 
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The first precondition in developing an enzyme inhibitor as drug is the identification of 
biomarker, meaning the proteases and their inhibitors that are differentially expressed 
in diseases. Secondly, identification of endogenous substrates, that target the proteas-
es. Nonetheless, it has proven to be complicated as protein target should have altered 
activity connected to differential expression in the disease of interest. However, in case 
of proteases the expression profile remains unchanged even by deregulation of activity 
resulting from increased activation or loss of a key inhibitor. (Katz et al. 2000; Turk 
2006) 
 
5.2 Structure of the Protease Active Site 
 
An active enzyme is defined by a binding pocket whose size, shape and charge deter-
mine the cleavage specificity of the substrate. The protease surface accommodating a 
single side chain of a substrate residue is called a subsite, which is numbered S1-Sn 
towards N terminus of the scissile bond and S1´-Sn´ towards C terminus of the scissile 
bond, the corresponding single side chain of the substrate is numbered P1-Pn and P1´- 
Pn´ respectively (Figure 5). (Copeland 2000; Turk 2006) 
 
 
Figure 5. Protein Substrate Binding to Protease. Subsite accommodates a single chain of a 
substrate residue and they are numbered S1-Sn upwards towards the N terminus non-primed 
sites and S1´-Sn´towards the C terminus primed sites. (Turk 2006) 
 
In serine proteases, substrates specificity and selectivity of inhibitors is conferred by 
the combination of the interaction series of inhibitor groups at subsites S3, S2, S1, S1´, 
S2´and S3´ binding peptide side chains. Trypsin-like serine proteases possess a S1 
binding pocket which has a conserved aspartate residue at position 189 that enable the 
specificity for non-polar P1 residues. Interactions at the S1 site enable small-molecule 
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inhibitors to discriminate between protease classes, thus achieving specificity for drug 
targets. (Copeland 2000; Katz et al. 2000) 
 
5.3 Catalytic Activity of Hepsin 
 
The crystal structure demonstrates how the extracellular component of hepsin might be 
positioned with respect to the plasma membrane. The extracellular stem region is 
formed by two domains of which the larger is structurally homologous to the members 
of the (chymo)trypsin superfamily of serine proteases, and smaller is scavenger recep-
tor cysteine-rich (SRCR) domain. The Pro50 residue of the SRCR domain constrains 
the spatial relation between the extracellular stem region and the entrance to the mem-
brane (Figure 6). (Somoza et al. 2003; Xuan et al. 2006) 
 
 
Figure 6. Structure of Human Hepsin. (Somoza et al. 2003) 
 
Since there is no peptide bond linking the two domains, the proteolytic activation step 
of hepsin requires hydrolyzation of the peptide bond between Arg162 and lle163, thus 
separating the serine protease domain from the rest of the protein. The two chains, 
pro- and catalytic domains, remain covalently bound to each other in activated form 
through a disulfide bond between Cys277 of the serine protease domain and Cys153 of 
the non-catalytic chain. The active hepsin possesses a conserved aspartate residue at 
the bottom of the S1 binding pocket in the activated SPD, which determines the prefer-
ence for cleavage of substrates with a basic amino acid. (Somoza et al. 2003) 
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6 Objective 
 
The aim of the thesis was to develop two different enzymatic platforms to use as a 
compound library screening method for drug discovery assisted by virtual screening. 
The first platform was a biochemical assay that measures the activity of recombinant 
hepsin based on commercial protocol. The second platform was a cell-based, measur-
ing the activity of the enzyme produced by the cells (Figure 7). 
 
 
Figure 7. Schematic of Assay Development.  
 
Development was done in two phases: In the first phase, a biochemical activity assay 
based on commercial protocol was optimized and further developed. In the second 
phase, a cell-based assay was developed. Both platforms were tested for functionality 
whereby a compound screening was performed. 
7 Methodology Including Methods and Materials 
 
The development of the enzymatic assay was based on the activity assay protocol by 
R&D Systems (Appendix 1) using recombinant human hepsin (rhHepsin) derived from 
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mouse myeloma cell line (R&D Systems) and fluorogenic peptide substrate BOC-Gln-
Arg-Arg-AMC (BOC). The activity of the recombinant human hepsin is measured by its 
ability to cleave tert-butoxycarbonyl-Gln-Arg-Arg-7-amino-4-methylcoumarin. BOC-Gln-
Arg-Arg-AMC is AMC-based substrate for transmembrane serine protease hepsin, 
which means that 7-Amino-4-methylcoumarin (AMC) can be used as fluorescence ref-
erence standard. 
 
Basic Assay procedure contained a 96-well plate (ViewPlate®-96 F TC, Perking Elmer 
Lot 9508512) used in all measurements, activated rhHepsin (Catalog #4776-SE), 
fluorogenic peptide substrate BOC (Bachem, Catalog #I-1655) and Assay Buffer 50mM 
Tris, pH 9.0. Assay Buffer was used as a blank in measurements as well as dilution 
substance for rhHepsin and BOC, where the dilution ratio was modified according to 
desired concentration. The requirement for the measurement with 96-well plate includ-
ed 100 µl substances in the well in total, wherein the pipetting volumes of different sub-
stances were modified over the course of experiments in to their final volumes. 
 
In the beginning, the experiments were conducted with extensive limits and ranges in 
order to gather sufficient data for profound assessment, including measurement time of 
55 minutes as well as substance concentrations. In course of experiments these limits 
and ranges were modified according to the kinetic reaction model of rhHepsin. Devel-
opment process was iterative; hence measurements had to be repeated in certain or-
der while modifying the parameters. 
 
7.1 Measurement Instrumentation and Data Analysis 
 
Measurements were conducted with Fluostar Omega (BMG Labtech 2014) Multi-Mode 
Microplate reader using fluorescence intensity detection and top read mode. Fluostar 
Omega had relatively new features compared to conventional spectrophotometer mod-
els such as adjustable gain control that enhances photomultiplier tubes responsiveness 
to the signal intensity. Hence, measured signal could be optimized to the dynamic 
range. There were also different modes for well reading as well as amount and intensi-
ty of the flashes used in order to enhance the sensitivity. All these features had to be 
optimized in course of experiments in order to find the best possible parameters for 
assay measurements. 
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Data was analyzed with Graph Pad Prism 6 (©2014 GraphPad Software, Inc) statistical 
data analysis tool which is designed for scientific use. In addition to usual statistical 
methods, Graph Pad Prism has linear and nonlinear regression curve fitting methods 
for enzyme kinetics and dose-response models, although using them requires under-
standing of mathematical models.  
 
7.2 Instrumentation Setup 
 
Before setting up the assay, it was important to establish the range and linearity of in-
strument performance, in order to determine the linear range of the measurement as 
described in Assay Guidance Manual: Basics of Enzymatic Assays by Brooks H. B. 
2012. This applies particularly to enzymatic reactions where the reaction reaches plat-
eau due to product formation, hence it is important to distinguish progress curve from 
signal saturation. Signal saturation occurs when upper detection limit is reached and an 
increase in substance concentration no longer raises the signal levels. Therefore, the 
detection system becomes non-linear outside of the linear range of the instrument and 
detected product concentration is less than the total product concentration. The linear 
range of the measurement system is defined as the linear portion of the dynamic range 
which is delimited by upper and lower detection limit. 
 
For any subsequent assay analysis and establishing assay parameters, it was essen-
tial to perform enzyme reaction conditions within this linear range. Instrument perfor-
mance and system linearity is closely linked to defining initial velocity conditions as 
described in the following chapters. 
 
7.3 Enzyme Reaction Progress Curve 
 
All information necessary to analyze an enzymatic reaction can be obtained via reac-
tion progress curve. Analyzing enzymatic reaction is a key feature in establishing assay 
conditions and basic parameters, such as enzyme and substrate concentrations, as 
well as Km and IC50 values.  
 
Following sections describe the process in detail as reviewed from Assay Guidance 
Manual: Basics of Enzymatic Assays for HTS by Iversen H. B. 2012. Methodology to 
determine initial velocity conditions via active site titration and establishing Km and Vmax 
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were reviewed from Enzymes: A Practical Introduction to Structure, Mechanism, and 
Data Analysis by Copeland R. A. 2000, as well from Evaluation of Enzyme Inhibitors in 
Drug Discovery: A Guide for Medicinal Chemists and Pharmacologist by Copeland R. 
A. 2013. 
 
7.3.1 Determination of Initial Velocity Conditions 
 
Determining initial velocity conditions of the given enzymatic reaction is considered as 
a basis in establishing enzyme assay parameters and a first requirement for steady 
state conditions. Beyond initial velocity conditions, the enzymatic reaction is affected by 
product inhibition, reverse reaction and substrate limitation as saturation of the enzyme 
with substrate decreases. These factors contribute to non-linear reaction in proportion 
to enzyme concentration whereby the substrate concentration remains unknown. Fur-
thermore, there is a greater possibility of saturation of the detection system. 
 
Therefore, the first step in establishing any of the above mentioned assay parameters 
the initial assay condition had to be determined. Initial velocity is defined as the initial 
linear portion of the enzyme reaction, when less than 10 % of the initial substrate con-
centration has been converted to product (Figure 8). 
 
 
Figure 8. Initial Velocity of the Enzymatic Reaction Progress Curve. (Copeland R. A. 2000) 
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Initial velocity and reaction time is dependent on the given substrate and enzyme and 
their concentrations. In order to establish the initial velocity conditions, the enzyme 
concentration had to be modified to maintain linearity in respect to measurement time. 
This could be obtained via active site titration. 
 
7.3.2 Active Site Titration and Titration Matrix 
 
The active enzyme concentration can be determined by active site titration for enzymes 
that demonstrate burst phase kinetics due to covalent intermediate formation, such as 
serine proteases. In burst phase kinetics, the overall reaction is rate-limited by decom-
position of the intermediate species, which leads to rapid build-up of the intermediates 
before reaching steady state velocity. Therefore, the concentration of active enzyme is 
identical to that of intermediates and can be determined from the intercept value of a 
linear fit of the data in the steady state phase. 
 
Enzyme concentration was optimized combining active site titration and two factor de-
sign screening into titration matrix (Table 1), since enzyme titration requires multiple 
concentrations, whereby full level design would be extensive and time-consuming.  
 
Table 1. Titration Matrix. 
 
rhHepsin 1st Titration 2nd Titration 
[nM] 50 BOC [µM] 25 BOC [µM] 12.5 BOC [µM] 50 BOC [µM] 25 BOC [µM] 12.5 BOC [µM] 
25 X X X - - - 
12.5 X X X X X X 
6.25 X X X X X X 
3.13 X X X X X X 
1.56 X X X X X X 
0.781 X X X X X X 
0.391 X X X X X X 
0.195 - - - X X X 
0.098 X X X X X X 
0.049 X X X X X X 
0.024 X X X X X X 
 
Screening is best suited for fast and approximate determination of possible location of 
optimum sample point, and is based on bracketing the obtained response surfaces of 
the sample points close to the optimum. Each enzyme concentration was titrated with 
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2x, 1x and 0,5x levels of substrate concentration in order to analyze the reaction line-
arity.  
 
The kinetic reaction model of rhHepsin would indicate that the optimum enzyme con-
centration is below the concentration of 0.391 nM. Therefore, the bracketing was start-
ed between the concentrations of 0.391 nM and 0.098 nM continuing below these val-
ues in the titration matrix (Table 2). 
 
Table 2. Titration Matrix After Bracketing. 
 
rhHepsin 1st titration 2nd titration 
[nM] 50 BOC [µM] 25 BOC [µM] 12,5 BOC [µM] 50 BOC [µM] 25 BOC [µM] 12,5 BOC [µM] 
0.15 X X - X X - 
0.075 X X - X X - 
0.0375 X X - X X - 
0.01875 - - - X X - 
 
Lower levels of substrate were excluded as they yielded reaction rates too slow for 
assessment. Furthermore, a very low enzyme concentration of 0.01875 nM was in-
cluded for further analysis. 
 
7.3.3 Enzyme Kinetics Model 
 
A detailed enzyme kinetics analysis was performed in order to evaluate possible 
sources of variation, such as processing time, light and temperature changes. Titration 
matrix was designed for evenly spaced enzyme concentrations and 4 substrate levels 
(Table 3). 
 
Table 3. Titration Matrix for Enzyme Kinetics. 
 
rhHepsin Titration 
[nM] 30 BOC [µM] 25 BOC [µM] 15 BOC [µM] 5 BOC [µM] 
0.8 X X X X 
0.7 X X X X 
0.6 X X X X 
0.5 X X X X 
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[nM] 30 BOC [µM] 25 BOC [µM] 15 BOC [µM] 5 BOC [µM] 
0.4 X X X X 
0.3 X X X X 
0.2 X X X X 
0.1 X X X X 
0.05 X X X X 
0.025 X X X X 
0.0125 X X X X 
 
Enzyme kinetics model required comparable processing of assay preparation in order 
to minimize any influences of unwanted factors. Especially, the assessment of these 
factors became of importance for the functionality of the assay. 
 
7.3.4 Determination of Km and Vmax 
 
For an enzymatic reaction, a Km value is usually defined as the substrate concentration 
that results in half-maximal velocity of the given enzyme-substrate reaction. Km can 
also be defined as a substrate concentration at which half of the enzyme active sites 
are saturated by substrate molecules in the steady state. Defining Km concentration for 
the substrate is of importance so that the enzymatic reaction can be run under steady 
state conditions. In this way, the reverse reaction will not affect the reaction. The value 
of Km is specific to a given enzyme-substrate reaction and to their concentrations. 
 
The value of Km can be determined accurately only under initial velocity conditions, 
which is also of importance for identification of competitive inhibitors, the common goal 
of SAR. Competitive inhibitor activity in a competition experiment that measures IC50 
values can be identified by a substrate concentration at or below Km value. In this way 
the velocity of the reaction is insensitive to changes in substrate concentration. The 
value of Vmax describes the maximal reaction rate of the given enzyme-substrate reac-
tion which however will be reached only theoretically. 
 
In order to measure IC50 values of competitive inhibitors, a substrate concentration 
around or below Km had to be determined as higher substrate concentrations would 
aggravate the identification of competitive inhibitors. A large excess of substrate over 
enzyme had to be used in order for steady state conditions to be met, whereby a 2-fold 
dilution scheme was used covering nine different substrate concentrations varying over 
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the range of 0.2-5.0 Km.  The measurement had to be repeated 5 times, from which the 
average Km was calculated. 
 
Assessment was carried out using Graph Pad Prism 6 software, where each reaction 
was analyzed using linear regression in order to obtain the slope of the reaction. Slope 
(v0), is defined as the change in the product formed divided by the change in time i.e. 
reaction rate. Subsequently, the obtained slope values of each measurement were 
analyzed via non linear regression that calculates Km and Vmax saturation curve using 
rectangular hyperbola. Compared to Lineweaver-Burk, rectangular hyperbola is con-
sidered more accurate, since an enzymatic reaction that follows Michaelis-Menten ki-
netics will form a rectangular hyperbola when initial velocity reaction is plotted against 
substrate concentration, whereas Lineweawer-Burk is a variable of the same equation 
only that it is subjected to measurement errors and the method of least squares is theo-
retically no longer applicable. 
 
7.4 Usage of DMSO and DMSO Compatibility 
 
DMSO at a concentration of 100 % were used as a test compound dissolvent and 
therefore DMSO concentration of the assay had to be determined in the early devel-
opment phase. DMSO concentrations from 0 % to 5 % were tested under uninhibited 
assay conditions in order to determine the solvent-compatibility of the assay and reac-
tion inhibition due to DMSO. Furthermore, variability studies had to be performed with 
the final DMSO concentration. For cell-based assays, it is recommended that the final 
DMSO concentration should not exceed concentration of 1 % to ensure the cell viabil-
ity.  
 
7.5  Determination of IC50 
 
The value of IC50 is defined as the concentration of substance that provides an inhibi-
tion of 50 % of the enzymatic reaction. According to Assay Guidance Manual: Guid-
ance for Assay Development & HTS by Eastwood et al.: 
 
Substantial variation in the methodology used to derive these values exists, and this vari-
ation has been shown to substantially impact overall assay variability (Eastwood et al. 
2007,p.41). 
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Although it usually remains unstated, the IC50 is commonly defined as relative IC50 val-
ue instead of absolute IC50 value which has its own applications. There are several 
guidelines for dose-response curve fitting of IC50 value that will not be discussed in 
detail, since the curve fitting as well as data assessment generally were done with 
Graph Pad Prism.  
 
Relative IC50 is recommended in context of assays and there are three methods to fit 
the curve. For all three methods in common is that it has to be decided how to fit the 
top and bottom plateau of the curve. The main points of curve fitting from Graph Pad 
Prism 6 User Guide will be reviewed below: 
 
1. Fit the curve by excluding the Blank and NS control values, i.e. using the data 
only for curve fitting. 
2. The parameter Top is defined as constant equal to the average value of Blanks. 
The parameter Bottom is defined as constant equal to the average value of NS 
controls.  
3. Blank values are fitted as part of the dose-response curve by entering them as 
low dose, because zero is not defined on a log-scale. NS controls are fitted as 
part of the dose-response curve by entering them as a very high concentration 
of inhibitor. 
 
Nonetheless, all three methods result in a very similar IC50 value, where top and bottom 
plateaus are indistinguishable and a complete dose-response curve is formed. In this 
case, the first choice was used for dose-response curve fitting as well as Graph Pad 
Tool Ecanything that enabled the inhibition-% analysis of any point along the dose-
response curve. Before the actual curve fitting, the concentrations of the data had to be 
transformed in to a log-scale by transform tool build in Graph Pad Prism. 
 
7.6 Plate Uniformity and Signal Variability Studies 
 
Plate uniformity and signal variability studies are usually done as a part of the valida-
tion process of enzymatic assays as described in Assay Guidance Manual: HTS Assay 
Validation by Iversen P. W. 2012.  Although the assay will not be validated in context of 
this thesis, these studies were selected in order to ensure the functionality of the assay 
performance. The plate uniformity assessment ensures that the plate format used for 
measurements has no edge or drift effect or other systematic sources of variability on 
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the signal. On the other hand, signal variability assessment ensures that the signal 
separation of raw signals is enough to conduct screening.  
 
The plate uniformity study was performed with Interleaved-Signal format which runs all 
signals on all plates varying them systematically so that over all plates on a given day 
each signal is observed in each well. The Interleaved-Signal format can be used in all 
instances and is run for three days with three plates per day respectively for new inval-
idated assays (Appendix 2). The signal variability assessment was performed on three 
types of signals: 
 
1. “Max” Signal measures the maximum signal which consists of negative control 
including DMSO according to assay design concentrations. 
2. “Mid” Signal measures the midpoint signal i.e. IC50 concentration of positive 
control according to assay design concentration. 
3. “Min” Signal measures the background signal which consists of assay buffer in-
cluding DMSO according to assay design concentrations. 
 
Plate acceptance criteria for the assay design were defined as follows: The raw signals 
are tight and there is enough separation between maximum and minimum signals to 
conduct screening. The average rate of outliers is less than 2 %. The coefficient of var-
iation of each signal is less than or equal to 20 %. Standard deviation of midpoint signal 
is less than or equal to 20 on all plates. Signal window is more than or equal to 2 on all 
plates or Z´ factor is more than or equal to 0.4 on all plates. Drift may not exceed 20 % 
as this is considered to be material drift. Edge effect has no acceptance limit however it 
may be a helpful troubleshooting technique as it may reveal that the incubation tem-
perature is reached unevenly in the wells across the plate. Universally, no material 
edge, drift or other spatial effects are allowed. In Inter-plate and Inter-Day tests the 
normalized average midpoint signal should not translate into a fold shift of more than 
two within days or more than two across any two days. 
 
7.7 List of Compounds 
 
The name and molecule structure of the compounds were confidential. Therefore, the 
compounds were identified per Lab No. which was used in laboratory context and per 
ID in context of traceability (Table 4).  
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Table 4. List of Compounds. 
 
List of Compounds 
Lab No. ID Lab No. ID 
n/a NTH1 12 1571 
1 9128 13 0031 
2 6777 14 3560 
3 0356 15 7865 
4 6934 16 6617 
5 2881 17 1908 
6 4684 18 2603 
7 1595 19 5174 
8 3129 20 5657 
9 4650 21 3081 
10 1907 22 5062 
11 5119 23 5975 
 
There were results available from previous compound screenings although with differ-
ent enzyme and substrate concentration. Unfortunately the screenings in question 
showed considerable variations and failed to deliver consistent results. Therefore, the 
development of the assay included also the aspect of tracing down the sources of vari-
ation in order to attain reliable results. 
 
7.8 Cell-based Assay Preparation and Optimization 
 
The cell line used for the cell culture was adherent human mammary epithelial cells 
MCF 10A (ATCC® CRL-10317™) that were lentivirally infected with pINDUCER-NEO-
HPN construct. Neo refers to neomycin/G418 selection (Meerbrey et al, 2011). MCF 
10A-pINDUCER-NEO-HPN cells were cultured in human mammary epithelial cell basal 
growths media MCDB 170 (US Biological) supplemented with bovine pituitary extract 
70 µg/ml, insulin 5 µg/ml, hydrocortisone 0.5 µg/ml, epidermal growth factor 5 ng/ml, 
transferin 5 µg/ml, Isoprotenol 10-5 M, Amphotericin B 50 µg/ml and Gentamicin 50 
µg/ml (all supplements obtained from Sigma). Cells were cultured in 2 cm 6 well plate, 
as well as 6 cm and 12 cm Petri-dishes (Greiner) and detached from the plates with 
Trypsin-EDTA (Gibco) 
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The cells were seeded in a 96-well plate (Perking Elmer) with the density of 50 000 cell 
per well and incubated 24 hours before the HPN gene was activated with 100 ng/ml 
Doxycyclin using MQ water as a carrier control. After activation of HPN gene the cells 
were incubated for another 24 hours before the measurement. 
 
For the final assay design, the cell amount and incubation time were optimized. The 
incubation time has to be sufficient enough for the cells to attach at the bottom of 96-
well plate, but also sufficiently short so that the cells will not lose their viability during 
the incubation. Loss of viability by the cells can be seen as uneven measurement re-
sults, as well as low fluorescence values during the measurement. The cell amount had 
to be optimized so that after the incubation the cells covered the bottom of the well in 
96-well plate and so that during the measurement there will be enough separation be-
tween fluorescence intensity induced by the cells and blank value. 
8 Results 
 
The following chapters describe the course of experiments in detail. The results of the 
experiments during assay development are found in paragraphs and appendices. 
 
8.1 Instrument Capacity and System Linearity 
 
The range and linearity of the instrument performance was determined by using 2-fold 
dilution scheme of reaction product AMC covering a 1024-fold concentration range. 
Before the actual calibration testing, the concentration of the AMC standard reference 
(1 mM stock solution) was adjusted using NanoDrop (Thermo Scientific 2010) in wave-
lengths of 350 nm and 355 nm (Appendix 3).  
 
In order to assess the decrease in fluorescence intensity, the measurement was set to 
55 minutes in five minutes intervals. Results were assessed with Graph Pad Prism 6 
using statistical evaluation of linear curve fitting with interpolation function that is de-
signed to recognize outliers, and also calculates the coefficient of variation. Only Blank 
(assay buffer) corrected values were used for assessment. The fluorescence intensity 
capacity of the equipment is evaluated up to 100 µM AMC in the first phase. 95 % con-
fident intervals are marked red (Figure 9). 
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Figure 9. System Capacity and System Linearity 0.098 µM – 100 µM. 
 
Second phase evaluates the linearity up to 6.25 µM AMC, as the preliminary experi-
ments show that the final product formation of the reaction lies around 5 µM AMC. The 
95 % confident intervals are marked red (Figure 10). 
 
 
Figure 10. System Capacity and System Linearity 0.098 µM – 6.25 µM. 
 
The enzymatic reaction of rhHepsin and BOC substrate is in the linear portion of the 
system linearity and detection limits. According to manufacturer’s specifications, the 
sensitivity of the Fluostar Omega corresponds to < 0.2 fmol/well Sodium Fluorescein, 
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which is below the measured minimum of 0.098 µM AMC standard reference. The 
equipment is capable of detecting fluorescence intensities up to 100 µM AMC although 
the linearity decreases above concentrations of 10 µM AMC, as well as during the 55 
minutes measurement (Appendix 4). 
 
The signal amplification of the equipment was further optimized by gain adjustment in 
order to ensure the maximum sensitivity and dynamic range for the conversion of AMC. 
The AMC reference standard was used for the optimization that resulted in 10 % target 
value and Gain value of 600. 
 
8.2 Initial Velocity Conditions 
 
The following chapters describe the steps taken to determine initial velocity conditions 
for the enzymatic reaction of recombinant hepsin and BOC substrate. Determining ini-
tial velocity conditions consists of active site titration and enzyme kinetics. 
 
8.2.1 Active Site Titration 
 
Titration matrix was designed for two titrations respectively (Table 1). In order to ana-
lyze the reaction progress curves, both titration matrices were assessed parallel ac-
cording to substrate concentration. For clarity, the higher and lower concentrations 
were excluded as they do not contribute to the overall assessment.  
 
When analyzing the reaction progress curves of both titration matrices, it becomes no-
ticeable that higher enzyme concentrations convert AMC relatively fast. The linearity, 
reaction time and plateau between the titration matrices vary greatly. Generally, the 
first titration with 50 µM BOC entailed shorter reaction times and higher plateaus com-
pared to the second titration, whereby linearity correlated better time-wise in the se-
cond titration (Figure 11). 
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Figure 11. Comparison of 1st and 2nd Titration Matrices 50 µM BOC. 
 
Both titrations with 25 µM BOC resulted in similar phenomena as in the titrations with 
50 µM BOC. The first titration resulted in shorter reaction times and higher plateaus 
compared to the second titration except for second titration with 1.563 nM rhHepsin. 
Also, the linearity correlated better time-wise in the second titration. (Figure 12). 
 
 
Figure 12. Comparison of 1st and 2nd Titration Matrices 25 µM BOC. 
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The titrations with 12.5 µM BOC conforms the previous results. The first titration result-
ed in shorter reaction times and higher plateaus compared to the second titration, 
wherein linearity correlated better time-wise in the second titration (Figure 13). 
 
 
Figure 13. Comparison of 1st and 2nd Titration Matrices 12.5 µM BOC. 
 
The most complex matter is that the reaction progress curves between the enzyme 
concentrations are not consistent as can be seen with the overlapping enzyme concen-
trations of 0.781 nM and 0.391 nM with all substrate concentrations. This may indicate 
to other unknown yet influencing factors in assay processing. Furthermore, the plat-
eaus within a titration do not converge, which is due to decrease in enzyme activity with 
time.  
 
Same phenomenon as in the previous measurements is particularly outlined in the titra-
tion matrices after bracketing (Table 2). The linearity, reaction time and plateau vary 
greatly between the titrations. The first titration resulted in shorter reaction times and 
higher plateaus compared to the second titration. The enzyme concentration of 0.15 
nM of the second titration is overlapping with the enzyme concentration of 0.075 nM of 
the first titration as well as the enzyme concentration of 0.075 nM of the second titration 
is overlapping with the enzyme concentration of 0.0375 nM of the first titration with the 
substrate concentration of 50 µM BOC (Figure 14). 
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Figure 14. Comparison of 1st and 2nd Titration Matrices 50 µM BOC After Bracketing.  
 
The enzyme concentration of 0.15 nM of the second titration is overlapping with the 
enzyme concentration of 0.0375 nM of the first titration, wherein the enzyme concentra-
tion of 0.075 nM of the second titration is below the enzyme concentration of 0.0375 
nM of the first titration with the substrate concentration of 25 µM BOC (Figure 15).  
 
 
Figure 15. Comparison of 1st and 2nd Titration Matrices 25 µM BOC After Bracketing. 
 
This concludes that the enzyme activity has decreased between the first and the se-
cond titration possibly due to inter alia light or higher temperatures during assay pro-
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cessing. In order to assess the loss of activity, as well as to determine the optimum 
enzyme concentration, a series of enzyme kinetics measurements were conducted 
 
8.2.2 Enzyme Kinetics 
 
Only the lowest 5 µM substrate level generated progress curves according to the levels 
of enzyme concentrations. Meaning, enzyme concentration 0.8 nM yielded the shortest 
reaction time and the highest plateau, enzyme concentration 0.7 nM yielded the se-
cond shortest reaction time and the second highest plateau and so forth (Figure 16a).  
 
In higher substrate levels, this enzyme concentration order is disrupted: Substrate level 
15 µM generated progress curves where enzyme concentrations 0.8 nM and 0.7 nM 
yielded similar reaction times, whereas 0.7 nM reached higher plateau, as well as en-
zyme concentration 0.5 nM had a shorter reaction time then 0.4 nM, which reached 
higher plateau nonetheless (Figure 16b).  
 
 
Figure 16. Enzyme Kinetics. a. Substrate level 5 µM. b. Substrate level 15 µM. c. Substrate 
level 20 µM. d. Substrate level 30 µM. 
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Similarly, substrate level 20 µM generated progress curves where enzyme concentra-
tion 0.8 nM yielded similar reaction time as 0.7 nM. However, the reached plateau of 
0.8 nM remained lower than in concentrations of 0.7 nM, 0.6 nM, 0.5 nM and 0.4 nM 
ending at the same level with the concentration of 0.3 nM (Figure 16c).  
 
The same phenomena are repeated in the progress curves generated with substrate 
level 30 µM. Enzyme concentration 0.8 nM yields shorter reaction time than 0.7 nM, 
whereas the reached plateau remains lower than 0.7 nM concentration. The same is 
repeated with enzyme concentrations 0.6 nM and 0.5 nM (Figure 16d). 
 
In conclusion, the equilibrium of enzyme-substrate reaction is sensitive to concentration 
changes in either one of the two substances and is influenced by such factors as prod-
uct inhibition, substrate limitation as well as reverse reaction as observed in the reac-
tion progress curves in figures 16a to 16d. Another interfering factor that can be ob-
served is the enzymes instability over time.  
 
On the basis of the results of enzyme kinetic experiments, the enzyme concentration 
was modified to 0.1 nM and the measurement time was cut to 30 minutes as the reac-
tion remains linear within this time. Notice: By further development the enzyme concen-
tration may be increased to 0.2 nM as the usage of DMSO inhibits the reaction and the 
measurement time cut down to 10 minutes or 15 minutes under the condition that the 
equipment is able to measure the reaction under initial velocity conditions. 
 
8.2.3 Enzyme Activity 
 
In the course of measurements, performed in enzyme kinetics, it became apparent that 
the enzyme recombinant hepsin shows instability over time. This means that if the en-
zyme remains stable under the test conditions, the reaction progress curves of each 
enzyme concentration ill converge until they reach similar maximum plateau value of 
product formation with the same substrate concentration. However, if the enzymes ac-
tivity decreases during reaction, the progress curves of different enzyme concentra-
tions will not converge and the tested enzyme concentrations do not reach the same 
maximum plateau value of product formation, as can be seen in figures 16a to 16 d. 
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8.3 Km and Vmax 
 
Initial velocity conditions were predetermined in the measurements described in section 
8.2. During the development, the Km & Vmax had to be determined several times due to 
erratic nature of the Km value, as well as when new enzyme Lot. was taken in use, 
since enzyme activity differs between batches. With the exception of one, all deter-
mined Km values (Appendix 5) were similar, of which was decided on the latest result 
17.76 µM (Figure 17). 
 
 
Figure 17. Determination of Km & Vmax. 
 
Since a substrate concentration around or below Km can be used as a guideline in de-
tecting competitive inhibitors, a substrate concentration of 15 µM was used in all sub-
sequent measurements. Recombinant hepsin concentration was set to 0.1 nM (See 
chapter 8.2.2). 
 
8.4 DMSO Compatibility 
 
DMSO compatibility was assessed with Graph Pad Prism, as well as with Excel calcu-
lations in order to gain a better understanding of the inhibition caused by DMSO. The 
DMSO concentrations above 2 % induce an inhibition of more than 90 %, when DMSO 
concentrations below 0.50 % induce an inhibition less than 30 % (Table 5).  
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Table 5. DMSO Compatibility. 
 
DMSO Inhibition  
0,05 % 6,98 % 
0,10 % 13,77 % 
0,25 % 12,40 % 
0,50 % 28,22 % 
0,75 % 32,01 % 
1 % 84,76 % 
2 % 90,46 % 
3 % 90,35 % 
4 % 91,72 % 
5 % 92,78 % 
 
Graph Pad Prism ECanything analysis gave for an inhibition of 5 % in the enzyme-
substrate reaction a DMSO concentration of 0.01 % (Figure 18). ECanything F5 (5 % 
inhibition) was analyzed using 30 minute end-point measurement. 
 
 
Figure 18. DMSO Compatibility. 
 
In connection with the Excel assessment, it was decided that final assay design should 
not contain a DMSO concentration above 0.5 %. In addition, a DMSO concentration of 
0.5 % causes a 5 % increase in background level. The final DMSO concentration of the 
compounds will be defined after establishing IC50 for Mid-level signal as the DMSO 
concentration has to be similar in positive control. 
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8.5 IC50 for Mid-level Signal 
 
IC50 was determined for compound NTH1, which is used as positive control in enzymat-
ic assay. There were two different NTH1 batches in use: NTH1 and NTH1 “new” which 
both gave similar IC50 values. 
 
IC50 was determined by using 3 fold dilution series covering the 50 000-fold concentra-
tion range, as well as half-log dilution series parallel that both resulted in similar values 
in each case. The first NTH1 batch that was in use NTH1 gave an IC50 value of 5.458 
µM (Figure 19). 
 
 
Figure 19. NTH1. 
 
IC50 value for the second batch NTH1 “new” was determined in a similar manner using 
3-fold dilution series parallel with half-log dilution series. The NTH1 “new” resulted to 
an IC50 value of 5.216 µM (Figure 20). 
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Figure 20. NTH1 ”new”. 
 
As NTH1 gave an IC50 value of 5.458 µM and NTH1 “new” an IC50 value of 5.216 µM, 
the Mid-level signal is set to 6 µM of NTH1. This is due to the guideline that mid-level 
signal concentration should be above the concentration that causes 50 % inhibition in 
enzyme-substrate reaction. This concludes as the final DMSO concentration 0.3 % in 
both compounds and positive control. 
 
8.6 Activity Loss 
 
In addition to enzyme instability, indications of activity loss by both positive control and 
screened compounds were apparent during preliminary compound screening (See 
chapter 8.8.2). Therefore, both NTH1 and a set of compounds were tested for activity 
loss under two different treatment conditions. A percentage difference was calculated 
between the compounds that underwent different treatment (Equation 1).  
 
Equation 1: Percentage Difference. 
 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 = �𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (𝐴𝐵)
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 (𝐴𝐵) � ∗ 100 
 
There were two different DMSO levels in the experiment: First level (-DMSO) present-
ing the enzyme-substrate reaction. Second level (+DMSO) presenting the enzyme-
substrate reaction including inhibition induced by 0.5 % DMSO. The activity loss exper-
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iments were conducted before establishing DMSO compatibility and IC50 for mid-level 
signal. 
 
8.6.1 Activity Loss of Positive Control NTH1 
 
In treatment condition one, the NTH1 “new” was kept frozen (0°C) for one hour before 
assay processing and preserved in ice during assay processing. In treatment condition 
two, the NTH1 “old” was allowed to reach room temperature (RT) during one hour be-
fore processing and preserved in room temperature during assay processing. 
 
 
Figure 21. Activity Loss by NTH1. NTH1 “new” was kept in 0°C and NTH1 “old” in RT. 
 
The activity loss of NTH1 was demonstrated, as NTH1 “old” presented no inhibition, in 
contrast to NTH1 “new”. The percentage difference resulted in 174 % difference in in-
hibition between the compounds under two treatment conditions “new” (0°C) and “old” 
(RT). (Figure 21). 
 
8.6.2 Activity Loss Screening of Compounds 
 
In treatment condition one, the compound (A) was kept frozen (0°C) for one hour be-
fore assay processing and preserved in ice during assay processing. In treatment con-
dition two, the compound (B) was allowed to reach room temperature (RT) during one 
hour before processing and preserved in room temperature during assay processing. 
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For the activity loss screening, ten compounds were selected according to previously 
measured activity levels. Activity levels were categorized as inhibition, enhancement 
and within limits, as no inhibition and no enhancement using ± 20 % cut-off limits. The 
± 20 % cut-off limits were calculated in relation to first DMSO level. Graphical analysis 
was performed for the second screening only, as in the first screening the used DMSO 
caused a total inhibition, which was due to the different DMSO Lots used in the labora-
tory, but in this point of development it had no effect to the evaluation. This complies 
also to the fact that the mid-level NTH1 concentration was also yet to be defined. Also, 
the negative fluorescence intensities were due to changes in baseline as the instru-
mentation automatically corrected the measured values. 
 
 
Figure 22. Activity Loss Screening, Compound 9128. a. 1st screening, b. 2nd screening. Com-
pound 1A is kept in condition A (0°C) and compound 1B in condition B (RT). 
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The compound 9128 remained within limits in both screenings after both treatment 
conditions A and B. Both screenings presented similar results, giving very low percent-
age difference between the two treatment conditions with 0.2 % in the first screening 
and 2 % in the second screening (Figure 22a-b). The graphical analysis of the com-
pound in relation to second level of DMSO (+DMSO) demonstrates enhancement in 
both treatment A and B. 
 
 
Figure 23. Activity Loss Screening, Compound 6934. a. 1st screening, b. 2nd screening. Com-
pound 2A is kept in condition A (0°C) and compound 3B in condition B (RT). 
 
The compound 6938 induced inhibition after treatment A in the first screening, whereby 
after treatment B the compound remained within limits (Figure 23a). In the second 
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screening the compound remained within limits after both treatment A and B (Figure 
23b). Percentage difference was relatively high with 49 %, in the first screening when 
the second screening presented lower 25 % difference between the two conditions. 
The graphical analysis of the compound in relation to second level of DMSO (+DMSO) 
demonstrates enhancement in both treatment A and B. The results indicate that the 
compound is sensitive to interfering factors. 
 
 
Figure 24. Activity Loss Screening, Compound 2881. a. 1st screening, b. 2nd screening. Com-
pound 3A is kept in condition A (0°C) and compound 3B in condition B (RT). 
 
The compound 2881 induced inhibition after both conditions A and B in both screen-
ings. Percentage difference between the conditions was relatively high with 61 % in the 
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first screening, whereby the second screening presented lower 24 % difference be-
tween the conditions (Figure 24a-b). The graphical analysis of the compound in relation 
to second level of DMSO (+DMSO) demonstrates slight enhancement in both treat-
ment A and B. 
 
 
Figure 25. Activity Loss Screening, Compound 3129. a. 1st screening, b. 2nd screening. Com-
pound 4A is kept in condition A (0°C) and compound 4B in condition B (RT). 
 
The compound 3129 induced inhibition after treatment B in the first screening, whereas 
after treatment A the compound remained within limits (Figure 25a). In the second 
screening, the compound induced inhibition after both treatment A and B (Figure 25b). 
Percentage differences in both screenings were relatively high with 34 % in the first 
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screening and 47 % in the second screening. The graphical analysis of the compound 
in relation to second level of DMSO (+DMSO) demonstrates slight enhancement in 
both treatment A and B. Results indicate that the compound is sensitive to interfering 
factors. 
 
 
Figure 26. Activity Loss Screening, Compound 1907. a. 1st screening, b. 2nd screening. Com-
pound 5A is kept in condition A (0°C) and compound 5B in condition B (RT). 
 
The compound 1907 induced inhibition after treatment B in the first screening, whereas 
after treatment A the compound remained within limits (Figure 26a). In the second 
screening, the compound induced inhibition after both treatment A and B (Figure 26b). 
Percentage difference in the first screening was relatively high with 41 % and very high 
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in the second screening with 78 %. The graphical analysis of the compound in relation 
to second level of DMSO (+DMSO) demonstrates enhancement after treatment B and 
within limits after treatment A. The results indicate that the compound is sensitive to 
interfering factors.  
 
 
Figure 27. Activity Loss Screening, Compound 5119. a. 1st screening, b. 2nd screening. Com-
pound 6A is kept in condition A (0°C) and compound 6B in condition B (RT). 
 
The compound 5119 remained within limits in both screenings after both treatment 
conditions A and B. Both screenings presented similar results, giving relatively low per-
centage difference between the two treatment conditions with 15 % in the first screen-
ing and 8 % in the second screening (Figure 27a-b). The graphical analysis of the 
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compound in relation to second level of DMSO (+DMSO) demonstrates enhancement 
in both treatment A and B. 
 
 
Figure 28. Activity Loss Screening, Compound 1571. a. 1st screening, b. 2nd screening. Com-
pound 7A is kept in condition A (0°C) and compound 7B in condition B (RT). 
 
The compound 1571 enhanced the reaction in both screenings after both treatment 
conditions A and B. Interestingly, in the first screening, the percentage difference is 
relatively high with 75 %, whereas in the second screening the percentage difference is 
low with 5 % between both treatment A and B (Figure 28a-b). The graphical analysis of 
the compound in relation to second level of DMSO (+DMSO) demonstrates enhance-
ment in both treatment A and B. 
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Figure 29. Activity Loss Screening, Compound 1908. a. 1st screening, b. 2nd screening. Com-
pound 8A is kept in condition A (0°C) and compound 8B in condition B (RT). 
 
The compound 1908 induced inhibition after both conditions A and B in both screen-
ings. Percentage difference between the conditions was very high with 161 % in the 
first screening, and in the second screening with 553 % difference between the condi-
tions (Figure 29a-b). The graphical analysis of the compound in relation to second level 
of DMSO (+DMSO) demonstrates inhibition after treatment A, whereas the compound 
remained within limits after treatment B. 
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Figure 30. Activity Loss Screening, Compound 5174. a. 1st screening, b. 2nd screening. Com-
pound 9A is kept in condition A (0°C) and compound 9B in condition B (RT). 
 
The compound 5174 induced inhibition after treatment A, whereas after treatment B the 
compound remained within limits in both screenings (Figure 30a-b). Percentage differ-
ence in both screening was similarly high with 93 %. The graphical analysis of the 
compound in relation to second level of DMSO (+DMSO) demonstrates enhancement 
after treatment B and within limits after treatment A. The results indicate that the com-
pound is sensitive to temperature.  
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Figure 31. Activity Loss Screening, Compound 5062. a. 1st screening, b. 2nd screening. Com-
pound 10A is kept in condition A (0°C) and compound 10B in condition B (RT). 
 
The compound 5062 remained within limits in the first screening after both treatment A 
and B (Figure 31a). In the second screening, the compound remained within limits after 
treatment A, whereas the compound enhanced  the reaction after treatment B (Figure 
31b). Percentage difference in the first screening was relatively low with 5 % and rela-
tively high in the second screening with 44 %. The graphical analysis of the compound 
in relation to second level of DMSO (+DMSO) demonstrates enhancement after both 
treatment A and B. The results indicate that the compound is sensitive to interfering 
factors. 
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The activity loss screening demonstrated the contradictory behavior of the screened 
compounds under two different treatment conditions. The results are outlined below 
(Table 6).   
 
Table 6. Summary of Activity Loss Screening. 
 
 
 
Data analysis excluded five of the compounds as unchanged activity in relation to first 
DMSO level with ± 20 % cut-off limits, whereas the other five demonstrated changed 
activity. However, the percentage difference and graphical analysis show that the com-
pounds have a tendency to enhance the reaction rate rather than inhibit the reaction. 
Depending on the treatment condition of the compound, the results showed significant 
variation. 
 
 
Compound Code Inhibition Within limits Enhanc. Percentage Inhibition Within limits Enhanc. Percentage
1A x x
1B x x
2A x x
2B x x
3A x x
3B x x
4A x x
4B x x
5A x x
5B x x
6A x x
6B x x
7A x x
7B x x
8A x x
8B x x
9A x x
9B x x
10A x x
10B x x
Explanatory description of the table:
Inhibition  and enhancement  are calculated using 20% -cut-off limits in relation to negative control.
Within limits  states that the compound does not exhibit any inhibition or enhancement in relation to 20% -cut-off limits.
Percentage  expresses the difference in activity between compound comparison pair.
Percentage difference  = (difference (AB)/average(AB))*100
Comparison pair  (A&B) expresses a compound that has undergone two different treatments.
Similar results  between activity loss screenings are expressed with the colour :
Differentiating results  between activity loss screenings are expressed with the colour:
Differentiating results  between compound comparison pair are expressed with frame:
46.82
1571
1908
5174
9128
6934
2881
3129 34.18
1st Activity Loss Screening 2nd Activity Loss Screening
0.23
49.90
61.26
2.32
25.61
24.03
43.76
78.63
7.74
5062
1907
5119
41.35
5.14
14.76
74.94
160.63
92.87
4.72
552.51
93.25
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8.6.3 Activity Reducing Factors 
 
Factors that reduce activity could be traced during assay processing and incubation, as 
temperature during the assay processing caused loss in activity in positive control 
NTH1 and some of the screened compounds. The 30 minute incubation time seems to 
be the critical step for successful assay, as during the incubation the compounds are 
exposed to temperature changes inside the laboratory, as well as light. This can be 
seen as uneven incubation inside the 96-well plate, wherein the wells in the middle of 
the plate show significant evaporation in contrast to the wells on the edge. 
 
8.7 Final Assay Design 
 
The final assay design includes two negative control, namely -DMSO that contains only 
the enzyme-substrate combination and +DMSO that includes 0.3% DMSO. The nega-
tive control -DMSO is included as internal control, since during the previous measure-
ments the differences in DMSO batches led to significant variation in results. The con-
centration of positive control NTH1 is set to 6 µM, wherein the compound concentration 
must also be 6 µM. Concentration of rhHepsin is 0.1 nM and BOC substrate 15 µM. 
Measurement time was optimized to 30 minutes and the equipment was optimized to 
gain value of 600 with 10 % target value. The final assay design is used for plate uni-
formity and signal variability assessment as well as for final compound screening. 
 
8.8 Plate Uniformity and Signal Variability Assessment 
 
The overall requirement for signal variability and plate acceptance criteria is met to 
conduct screenings. There were no outliers detected and all plates passed the ac-
ceptance criteria for max, mid and min signals, where each signal had a Coefficient of 
Variation less or equal to 20 %. Furthermore, the raw signals were sufficiently tight and 
there was enough separation between max and min signals (Figure 32). 
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Figure 32. Signal Variability, All Signal Levels. Each plate is plotted against fluorescence inten-
sity [FI]. 
 
Midpoint percent inhibition for each mid-signal well passes the criteria. Mid-signal wells 
in each plate had a standard deviation less or equal to 20 %, day 1 plate 3 displaying 
unusual tight signals (Figure 33). 
 
 
Figure 33. Midpoint Percent Inhibition, All Plates. Each plate is plotted against percentage inhi-
bition [%]. 
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As the validation checklist shows, all criteria for inter-plate tests are met. For intra-plate 
tests all criteria is met, except for the spatial uniformity assessment containing drift and 
edge effects (Table 7).  
 
Table 7. Validation Checklist. 
 
 
 
Unfortunately, spatial uniformity assessment failed as there were several drift effects 
and edge effects detected in the plates. In five cases, the max signal displayed drift 
effect, where the drift was more than 20 % and one case of mid signal displaying drift 
effect of 30 %. Edge effects were detected as the last column in each plate gave val-
ues far below the mean. Systematical source of variation can be seen as each plate 
displayed values that were decreasing from left to right in each row and from top to 
bottom in each column. 
 
8.9 Compound Screening 
 
Before the actual and final compound screening, a series of preliminary screenings 
were performed in order to gain a better understanding of the compound functionality. 
Preliminary experiments were also necessary for the assessment of assay develop-
ment as seen in chapter 8.6.  
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The actual and final compound screening was performed with the final assay design 
after performing plate uniformity and signal variability assessment (See chapter 8.7). 
Furthermore, the compound screening was performed three times similarly and as-
sessed together with the preliminary screenings. 
 
8.9.1 Preliminary Compound Screening 
 
The preliminary compound screening was performed in four screenings altogether, 
using partially different compounds. Each compound was evaluated using ± 20 % cut-
off limits in relation to negative control, namely +DMSO. 
 
In the first screening, from the tested compounds, Compound 1908 resulted in 22 % 
and Compound 5174 in 18 % inhibition in relation to negative control. All other com-
pounds were within ± 10 % in relation to negative control. Positive control (NTH1) re-
sulted in 85 % inhibition in relation to negative control (Figure 34). 
 
 
Figure 34. First Preliminary Screening. 
 
In the second screening, several compounds resulted in more than 20 % inhibition in 
relation to negative control. In the first diagram, Compound 3129 resulted in 18 % inhi-
bition when all other compounds were within ± 10 % limits. Positive control resulted in 
68 % inhibition in relation to negative control (Figure 35). 
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Figure 35. Second Preliminary Screening, 1st Diagram. 
 
In the second diagram, it can be seen how compounds 2881, 6934 and 9128 resulted 
in over 20 % inhibition in relation to negative control. The two other compounds were 
within ± 20 % cut-off limits (Figure 36). 
 
 
Figure 36. Second Preliminary Screening, 2nd Diagram. 
 
None of the tested compounds inhibited the reaction in the third screening; instead they 
enhanced the conversion rate of AMC. In the first diagram, the compounds 5062 and 
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5975 enhanced the reaction with over 75 %, wherein the remaining compounds en-
hanced the reaction more than 20 % (Figure 37). 
 
 
Figure 37. Third Preliminary Screening, 1st Diagram. 
 
In the second diagram, Compound 1907 remained within 10 % limits, wherein all other 
compounds enhanced the conversion rate more than 20 % in relation to negative con-
trol +DMSO. Furthermore, as seen in both diagrams, the positive control NTH1 is not 
inhibiting the reaction rate and is within 10 % limits (Figure 38). 
 
 
Figure 38. Third Preliminary Screening, 2nd Diagram. 
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In the fourth screening, the Compound 3560 inhibited the conversion rate by 42 %, 
wherein from remaining compounds all were within 20 % cut-off limits with the excep-
tion of compounds 1571 (68 %) and 6617 (81 %). On a further note, the positive control 
NTH1 inhibited the reaction rate of AMC conversion only by 13 % (Figure 39). 
 
 
Figure 39. Fourth Preliminary Screening. 
 
During preliminary compound screening, it became apparent that the compounds as 
well as positive control NTH1 lost their activity during the screening. Furthermore, 
some compounds enhanced the conversion rate of AMC significantly, although in pre-
vious screening they inhibited the conversion rate of AMC. 
 
8.9.2 Final Compound Screening 
 
After finalizing the assay design, the selected compounds were screened three times in 
a row in order to recognize potential drugs targeting rhHepsin, as well as to ensure the 
functionality of the assay design.  
 
Compounds were selected based on preliminary screening, including previously reac-
tion inhibiting compounds and one additional NTH1 “Misa” that had proven to inhibit the 
reaction. For the final screening compounds were kept in 0°C during the assay pro-
cessing and protected from light during 30 minute incubation. Factors that could not be 
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influenced during the assay processing and incubation, were changes in room temper-
ature and exposure to light between assay procedures. 
 
 
Figure 40. Final Compound Screening, 1st Screening. 
 
In the first screening, compounds 3129 and 1907 inhibited the reaction with more than 
20 % (Figure 40, Diagram 2) and NTH1 “Misa” with 98 % (Figure 40, Diagram 3). Re-
maining compounds were within ± 20 % cut-off limits except, for Compound 7865 that 
enhanced the reaction with 97 % (Figure 40, Diagram 3). 
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Figure 41. Final Compound Screening, 2nd Screening. 
 
None of the compounds in the second screening inhibited the reaction except for NTH1 
“Misa” with 97 % (Figure 41, Diagram 3). Five of the compounds were within ± 20 % 
cut-off limits, wherein remaining compounds enhanced the reaction i.e. Compound 
1571 with 97 % (Figure 41, Diagram 2) and Compound 7865 with 240 % (Figure 41, 
Diagram 3).  
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Figure 42. Final Compound Screening, 3rd Screening. 
 
The third screening gave similar results as none of the compounds inhibited the reac-
tion except the NTH1 “Misa” with 98 % (Figure 42, Diagram 3), whereas three of the 
compounds enhanced the reaction i.e. compound 7865 with 160 % (Figure 42, Dia-
gram 3). Remaining compounds were within ± 20 % cut-off limits (Figure 42).  
 
After summarizing the assessment of preliminary screening and final screening, none 
of the compounds showed specifically to inhibit, to remain within ± 20 % cut-off limits or 
to enhance the reaction. On the other hand, each of the screened compounds, with the 
exception of “NTH1” Misa, demonstrated at least two of three reaction patterns. The 
results are outlined below (Table 8). 
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Table 8. Summary of Compound Screening. 
 
 
 
After analyzing the results using ± 20 % cut-off limits, it can be concluded that using a 
broader range of cut-off limits would not incluence the overall assessment. It is evident 
that the screened compounds may either inhibit or enhance the reaction depending on 
the conditions throughout the assay procedure. The results with obtained values are 
outlined below (Table 9). 
 
 
 
 
 
 
 
 
 
Preliminary Screening Final Screening
Date 11.02.2014 11.02.2014 11.02.2014 11.02.2014 27.04.2014 27.04.2014 27.04.2014
Lab No. ID 1st Screen 2nd Screen 3th Screen 4th Screen 5th Screen 6th Screen 7th Screen
1 9128 YES ENH 
2 6777 NO ENH NO ENH NO
3 0356 NO ENH NO ENH NO
4 6934 YES ENH NO ENH NO
5 2881 YES ENH NO ENH NO
6 4684 NO ENH NO ENH NO
7 1595 NO ENH NO ENH NO
8 3129 NO ENH YES ENH NO
9 4650 NO ENH NO NO ENH NO
10 1907 NO NO NO YES NO NO
11 5119 NO
12 1571 ENH NO ENH ENH
13 0031 NO NO NO NO
14 3560 YES
15 7865 NO ENH ENH ENH
16 6617 ENH NO ENH NO
17 1908 YES ENH NO NO ENH NO
18 2603 NO ENH NO ENH ENH
19 5174 NO ENH NO ENH NO
20 5657 NO ENH NO NO NO
21 3081 NO ENH NO NO NO
22 5062 NO ENH 
23 5975 NO ENH NO NO NO
24 NTH1 "Misa" YES YES YES
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Table 9. Summary of Screenings Values in Percentage. 
 
 
 
Since the negative controls gave similar FI [355] values and the positive control NTH1 
inhibited the reaction from 68 % to 43 %, as well as NTH1 “Misa” showing very similar 
results, the assay design seems to work well.  
 
8.10 Preliminary Experiment Cell-based Assay 
 
The performance of the existing cell-based assay protocol was assessed in a series of 
preliminary experiments. The experiments were conducted under similar conditions, 
where each well contained 50 000 cells and -dox and +dox were run parallel. After 48 
hour incubation in the 96 well-plate, the conversion of AMC could be measured only in 
few wells (Figure 43). 
Preliminary Screening Final Screening
Date
Lab No. ID 1st Screen 2nd Screen 3th Screen 4th Screen 5th Screen 6th Screen 7th Screen
1 9128 -22,26 24,61
2 6777 -12,73 44,66 3,12 33,71 8,11
3 0356 -12,73 51,82 -4,65 21,58 3,51
4 6934 -32,66 35,26 -2,63 25,29 2,90
5 2881 -20,84 20,17 -9,97 21,88 -0,81
6 4684 -7,11 41,17 -13,03 23,52 -12,66
7 1595 -4,88 60,89 -10,96 36,14 2,87
8 3129 -17,92 32,91 -21,21 38,70 -2,85
9 4650 -9,54 36,54 13,23 -19,56 42,77 -16,10
10 1907 -5,65 2,30 19,69 -24,57 -13,11 -1,68
11 5119 14,13
12 1571 67,89 17,76 97,28 33,70
13 0031 10,21 0,67 18,62 9,39
14 3560 -42,05
15 7865 12,98 97,38 240,34 160,24
16 6617 81,45 2,39 32,42 15,93
17 1908 -22,18 26,49 15,14 -1,15 39,93 8,68
18 2603 -7,04 43,72 -12,64 70,90 34,58
19 5174 -18,05 21,05 -0,73 41,53 9,31
20 5657 -1,54 43,98 -12,07 13,91 -7,18
21 3081 -6,48 29,08 -13,79 16,25 2,39
22 5062 8,62 80,88
23 5975 -7,25 76,98 -18,06 14,93 -4,17
24 NTH1 "Misa" -98,09 -96,56 -98,01
Percentage in relation to negative control (reference value)
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Figure 43. Preliminary Experiment, Cell-based Assay. 
 
As doxycyclin had no influence on the results, possible reasons for large variation can 
be differences between cell viability in each well after the incubation time. As most 
wells showed no signs of reaction it can be assumed that the cells had lost their 
viability. 
 
8.11 Cell Amount and Incubation Time 
 
In order to adjust the cell amount and incubation time for high cell viability, a series of 
experiments were conducted. The series was performed in three days with three 96 
Well-Plate so that the cell were seeded at each plate at the same day with different cell 
amounts by row and each plate incubated different time (Appendix 6). Before measur-
ing, the 96 well-plates were inspected by microscope in order to ensure the cells fill the 
wells evenly. 
 
After a 24-hour incubation, the cell viability seems to be good as the reaction rates cor-
relate with the cell amounts in each well (Figure 44). Parallel measurements with doxy-
cyclin gave contradicting results as the higher cell amounts 150 000 cells and 70 000 
cells had faster reaction rates with -dox contrary to lower cell amounts where +dox 
gave higher reaction rates. The differences in results with doxycyclin treatment were 
not significant except in the 150 000 cell per well.  
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Figure 44. Cell Amount, 24 hours incubation. 
 
After a 48-hour incubation time, the variations between cell amount and doxycyclin 
treatment became apparent as the reaction rates did not correspond to cell amount. 
The wells that were not treated with doxycyclin had faster reaction rates with every cell 
amount, whereas the wells treated with doxycyclin containing 50 000 cells and 70 000 
cells resulted in very similar reaction rate being notably lower to 50 000 cells/well -dox 
(Figure 45). 
 
 
Figure 45. Cell Amount, 48 hour incubation. 
 
After a 72-hour incubation, there could not be measured conversion of AMC in any of 
the wells, which is most likely due to low cell viability. For cell viability the 24-hour 
incubation seems to be the best option. 
64 
 
  
8.12 Kinetics Cell-based 
 
Kinetic model for enzyme in cell-based assay was performed in the same manner as 
for biochemical assay (See chapter 8.2.2). Only in this case the enzyme measured was 
produced by the cells and the doxycyclin treated wells were measured parallel with the 
non-treated wells. 
 
Doxycyclin treated wells resulted in faster reaction rates in all cases except for 30 µM 
BOC, which gave slow reaction rates with doxycyclin treated and non-treated wells.  
The lower substrate concentrations resulted in faster reaction rates in all cases (Figure 
46). 
 
 
Figure 46. Kinetics, Cell-based Assay. 
 
These results can be considered as indicative due to low and too few substrate 
concentrations, as the reaction progress curve did not form saturation curve nore did 
reach plateau. The reaction progress curve also suggest that the cell viability may have 
been low in the most wells. 
 
8.13 Km and Vmax for Cell-based Assay 
 
Km and Vmax for cell-based assay was performed in same manner as for biochemical 
assay (See chapter 8.3). As there were no previous results indicating possible value for 
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Km, the substrate concentrations were distributed using 2-fold dilution scheme from 
1000 µM covering 1024-fold concetration range. 
 
Whereas  the results for Km in biochemical assay were constant containing only little 
variation, the results for Km in cell-based assay were not unambiguous. The average of 
five measurements gave 36.50 µM for Km value 1510 (pmol/min/ug) for Vmax (Figure 
47). 
 
 
Figure 47. Km & Vmax, Cell-based Assay. 
 
These results can be considered as indicative as the results contained large variations 
and as previous results show, higher than 36.50 µM substrate concentrations will not 
form saturation curve indicating a higher Km value. In addition, the cell viability should 
be further examined as well as the usage of doxycyclin. Running parallel measure-
ments with doxycyclin has displayed contradictory results leading to question if 
doxycyclin has an additional effect to the enzyme-substrate equilibrium. 
9 Conclusion and Discussion 
 
The development of cell-based assay could not be finalized in context of this thesis due 
to the extent of the project and lack of time caused by replacement of the original 
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equipment. The biochemical assay could be completed with existing assay parameters 
and signal variability assessment, whereas the spatial uniformity assessment did not 
meet criteria due to material effects. 
 
9.1 Biochemical Assay 
 
Before the project began, the existing assay protocol delivered differentiating results as 
the screened compounds could not be measured twice with similar results. The positive 
control NTH1 behaved in same manner and the causes of variation could not be 
traced. Hence, the optimizing of the assay protocol contained the aspect of investigat-
ing sources of variation. When defining initial velocity conditions, first indications of the 
sources of variation could be seen during active site titration as parallel experiments 
resulted in very different reaction rates. The same phenomena were seen during pre-
liminary compound screening meaning timing and temperature control were necessary 
for functioning assay processing. In addition, the loss of activity of both the compounds 
and positive control NTH1 during the preliminary compound screening were significant. 
 
The above mentioned sources of variation can be controlled with the right setting. Fac-
tors that cannot be controlled by test set up include enzyme instability as seen in the 
enzyme kinetics measurement. In addition the enzyme concentration needed to be 
optimized to 0.1 nM as higher concentrations resulted in product inhibition, reverse 
reaction and substrate limitation as the conversion of AMC by BOC substrate is fast. 
The enzyme concentration can be further optimized to 0.2 nM with the prerequisite that 
the equipment is able to measure the reaction under initial velocity conditions. 
 
The DMSO compatibility limit was set to 0.5 % DMSO as this would cause an inhibition 
of 7 % in the reaction. The DMSO compatibility was done with the same DMSO used 
for compound dissolvent, and it would be advisable to verify the compatibility by new 
batches as there were several DMSO LOTs in use and they delivered differentiating 
results as seen in the activity loss screening. In addition, the DMSO causes an in-
crease in background level by concentration wise. 
 
The IC50 value for mid-level signal was determined as 6 µM positive control NTH1 as 
the guideline for IC50 is a concentration that causes more than 50 % inhibition in con-
version of AMC. In signal variability assessment, all criteria for all signal levels was met 
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for functioning assay design, wherein the spatial uniformity assessment failed due to 
material effects.  
 
The final compound screening affirmed the functioning of assay design as all signal 
levels delivered stable readings, whereas the positive control NTH1 decreased in ac-
tivity during the screening from 68 % inhibition to 48 % inhibition.  The screened com-
pounds delivered differentiating results that was caused by changes in room tempera-
ture during 30 minute incubation. The limits for decrease in activity for positive control 
can be further discussed as the assay design is working with the defined parameters. 
Another aspect is how to proceed with the temperature during incubation. In case the 
compound structure is robust, it will inhibit the reaction rate despite changes in room 
temperature as proved by positive control NTH1 and NTH1 “Misa”. Nonetheless, for a 
congruent assessment of the compounds, it would recommendable to control the incu-
bation temperature as this would exclude the possibility of non-functioning assay de-
sign and false positives. 
 
9.2 Cell-based Assay 
 
All results regarding cell-based assay can be considered indicative as the time scope 
was too limiting for thorough experimental design. Another aspect is the cell viability 
that would need further investigation as it is the main source of variation. According to 
the results, it would be recommendable to set up the assay after the cells have at-
tached to the 96-well plate keeping the incubation time uniform and as short as possi-
ble.  
 
As seen in cell amount and incubation time adjustment, the cell amount can be in-
creased if the incubation time is decreased. The experimental design consisted of 25 
000 cells per well to 150 000 cells per well as the cells to be seeded were growing too 
scarce for a larger scale experimental design. It is also possible that the cell viability 
was affected by scarce cell growth conditions. It would be advisable to run the experi-
ment with larger cell amount and range including several repetitions.  
 
The usage of doxycyclin illustrates another issue. The experiments run parallel with 
doxycyclin delivered contradictory results to a certain degree, but in this, point it cannot 
be concluded is this due to cell viability or due to some combined effect by doxycyclin 
with the substrate. 
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The development of cell-based assay can be continued by investigating further the 
above mentioned questions. The vital point is to ensure the cell viability after seeding 
the cells into a 96-well plate by taking into consideration the maximum amount of cells 
that can be seeded. Incubation time and the usage of doxycyclin also need further op-
timization. If these questions are solved, the development can continue by determining 
Km and Vmax, DMSO compatibility and signal levels for signal variability assessment. 
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Appendix 1. Activity Assay Protocol by R&D Systems 
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Appendix 2. Plate Format for Plate Uniformity and Signal Variation 
 
Interleaved-Signal format for three day three plate signal variation assessment. 
 
Plate 1
1 2 3 4 5 6 7 8 9 10 11 12
A H M L H M L H M L H M L
B H M L H M L H M L H M L
C H M L H M L H M L H M L
D H M L H M L H M L H M L
F H M L H M L H M L H M L
G H M L H M L H M L H M L
H H M L H M L H M L H M L
I H M L H M L H M L H M L
Plate 2
1 2 3 4 5 6 7 8 9 10 11 12
A L H M L H M L H M L H M
B L H M L H M L H M L H M
C L H M L H M L H M L H M
D L H M L H M L H M L H M
F L H M L H M L H M L H M
G L H M L H M L H M L H M
H L H M L H M L H M L H M
I L H M L H M L H M L H M
Plate 3
1 2 3 4 5 6 7 8 9 10 11 12
A M L H M L H M L H M L H
B M L H M L H M L H M L H
C M L H M L H M L H M L H
D M L H M L H M L H M L H
F M L H M L H M L H M L H
G M L H M L H M L H M L H
H M L H M L H M L H M L H
I M L H M L H M L H M L H
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Appendix 3. Adjustment of AMC standard Reference 
The Standard Reference was measured by NanoDrop (ThermoScientific 2010) in 
wavelengths of 350 nm and 355 nm. The standard stock dilution 1 mM was diluted ac-
cordingly to concentration measured by NanoDrop.. 
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Appendix 4. Results of System Capacity and Linearity 
Results of 55 minutes measrurement with eleven AMC concentrations. Blank values 
are excluded as the fluorescence intensities are blank corrected values. 
 
No.
AMC [µM]
0m
in
5m
in
10m
in
15m
in
20m
in
25m
in
30m
in
35m
in
40m
in
45m
in
50m
in
55m
in
1
100
190178,5
191449,5
190630,5
189875,5
189281
188716
188362
187447,5
186839
186616
186018,5
185423,5
2
50
123499,5
124034
123621,5
123197,5
122612,5
122104
121946,5
121490,5
121314,5
121099,5
120782
119853
3
25
71857,5
72091
71654
71352
71051,5
70842,5
70722
70333,5
70216,5
69959,5
69790,5
69279,5
4
12,5
39225
39394
39068,5
38987
38730
38629
38546,5
38333,5
38197,5
38075,5
37933
37759,5
5
6,25
20889,5
20982,5
20845,5
20701
20556,5
20402
20343,5
20203
20158,5
20120
20021,5
19872,5
6
3,125
11105
11191,5
11051,5
11000,5
10904,5
10816
10775
10719
10660,5
10636,5
10581
10491,5
7
1,5625
5839,5
5859
5823
5778
5715,5
5679
5649
5623,5
5577,5
5571
5546,5
5508,5
8
0,78125
1555,5
1567
1543,5
1537
1530,5
1518,5
1503
1498
1490,5
1493
1486,5
1469,5
9
0,390625
1475,5
1476,5
1467,5
1453,5
1442,5
1424,5
1413,5
1409,5
1406,5
1399
1386,5
1381
10
0,195313
752
758
751
747,5
742,5
736,5
729,5
723
715,5
717,5
712
704,5
11
0,097656
388
385,5
384
383
382
377,5
376,5
374,5
369
368,5
362
362
Dilution
Obtained Intensity values in 355nm
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Appendix 5.Best-fit values for Michaelis-Menten 
 
Results of five measurements with 95 % confidence intervals and standard error. 
 
Michaelis-Menten 
 
     Best-fit values 
     Vmax 398,6 357,4 395,3 304,2 281,2 
Km 14,78 13,27 17,45 16,22 16,53 
Std. Error 
     Vmax 36,18 43,68 33,09 48,92 45,36 
Km 4,729 5,852 4,962 9,011 9,169 
95% Confidence 
Intervals 
     Vmax 324,1 to 473,1 267,4 to 447,3 327,1 to 463,4 203,4 to 405,0 187,8 to 374,6 
Km 5,041 to 24,52 1,222 to 25,33 7,228 to 27,67 0,0 to 34,78 0,0 to 35,41 
Goodness of Fit 
     Degrees of Free-
dom 25 25 25 25 25 
R square 0,8167 0,6959 0,8538 0,6004 0,6053 
Absolute Sum of 
Squares 115119 182994 83447 194496 164491 
Sy.x 67,86 85,56 57,77 88,20 81,11 
Constraints 
     Km Km > 0,0 Km > 0,0 Km > 0,0 Km > 0,0 Km > 0,0 
      Number of points 
     Analyzed 27 27 27 27 27 
 
Michaelis-Menten 
 Best-fit values 
 Vmax 187,0 
Km 17,76 
Std. Error 
 Vmax 15,15 
Km 5,964 
95% Confidence Intervals 
 Vmax 149,9 to 224,1 
Km 3,170 to 32,36 
Goodness of Fit 
 Degrees of Freedom 6 
R square 0,9092 
Absolute Sum of Squares 2669 
Sy.x 21,09 
Constraints 
 Km Km > 0,0 
  Number of points 
 Analyzed 8 
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Appendix 6. Experimental Design for Cell Amound and Incubation Time 
 
 
 
 
Incubation 24 h
1 2 3 4 5 6 7 8 9 10 11 12
A  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 150 000 Cells / Well
B  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 100 000 Cells / Well
C  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 70 000 Cells / Well
D  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 50 000 Cells / Well
E  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 25 000 Cells / Well
F  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 10 000 Cells / Well
G
H
I
Incubation 48 h
1 2 3 4 5 6 7 8 9 10 11 12
A  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 70 000 Cells / Well
B  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 50 000 Cells / Well
C  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 25 000 Cells / Well
D  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 10 000 Cells / Well
E
F
G
H
I
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Incubation 72 h
1 2 3 4 5 6 7 8 9 10 11 12
A  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 50 000 Cells / Well
B  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 25 000 Cells / Well
C  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 10 000 Cells / Well
D  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX  -DOX  -DOX  -DOX  +DOX  +DOX  +DOX 5 000 Cells / Well
E
F
G
H
I
